Antengene Past Earnings Performance
Past criteria checks 0/6
Antengene has been growing earnings at an average annual rate of 23%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 30.1% per year.
Key information
23.0%
Earnings growth rate
39.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 30.1% |
| Return on equity | -53.3% |
| Net Margin | -944.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Antengene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 56 | -530 | 283 | 310 |
| 31 Mar 24 | 62 | -555 | 312 | 358 |
| 31 Dec 23 | 67 | -581 | 341 | 406 |
| 30 Sep 23 | 123 | -628 | 429 | 470 |
| 30 Jun 23 | 178 | -676 | 518 | 535 |
| 31 Mar 23 | 169 | -639 | 520 | 512 |
| 31 Dec 22 | 160 | -601 | 522 | 488 |
| 30 Sep 22 | 121 | -584 | 429 | 469 |
| 30 Jun 22 | 83 | -567 | 335 | 449 |
| 31 Mar 22 | 56 | -611 | 286 | 427 |
| 31 Dec 21 | 29 | -656 | 237 | 405 |
| 30 Sep 21 | 14 | -1,640 | 201 | 359 |
| 30 Jun 21 | -2 | -2,624 | 165 | 313 |
| 31 Mar 21 | -1 | -2,777 | 160 | 330 |
| 31 Dec 20 | 0 | -2,929 | 155 | 348 |
| 30 Sep 20 | 4 | -1,842 | 124 | 307 |
| 30 Jun 20 | 8 | -755 | 93 | 267 |
| 31 Mar 20 | 10 | -539 | 66 | 191 |
| 31 Dec 19 | 11 | -324 | 39 | 116 |
| 31 Dec 18 | 7 | -146 | 25 | 116 |
Quality Earnings: 722 is currently unprofitable.
Growing Profit Margin: 722 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 722 is unprofitable, but has reduced losses over the past 5 years at a rate of 23% per year.
Accelerating Growth: Unable to compare 722's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 722 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 722 has a negative Return on Equity (-53.29%), as it is currently unprofitable.